Two Form Vanguard For First US Rivals to Banzel Suspension
Two companies now hold final US approvals for generics of Eisai’s Banzel oral suspension. But patent-litigation settlements could delay the entry of Bionpharma and Hikma to market.
You may also be interested in...
Hikma has provided a trading update that sheds fresh light on plans for its delayed Advair generic, as well as revealing some new launches.
As the US pricing situation continues to bite, industry veteran and newly-appointed Hikma chief executive officer Siggi Olafsson is confident the company’s superior balance sheet and diversified business operation, spread across three regions, will provide a competitive advantage. Dean Rudge reports.
Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.